OBJECTIVE: To examine the efficacy and steroid sparing potential of methotrexate (MTX) in the treatment of polymyalgia rheumatica (PMR) without giant cell arteritis. METHODS: 43 patients with PMR were treated with MTX 7.5 mg/wk for 3 months. This dose was raised to 10 and finally 12.5 mg/wk MTX if the desired response was not obtained. RESULTS: No patient benefitted clinically or statistically from treatment with MTX. CONCLUSION: MTX is of no benefit in the treatment of PMR.
OBJECTIVE: To examine the efficacy and steroid sparing potential of methotrexate (MTX) in the treatment of polymyalgia rheumatica (PMR) without giant cell arteritis. METHODS: 43 patients with PMR were treated with MTX 7.5 mg/wk for 3 months. This dose was raised to 10 and finally 12.5 mg/wk MTX if the desired response was not obtained. RESULTS: No patient benefitted clinically or statistically from treatment with MTX. CONCLUSION:MTX is of no benefit in the treatment of PMR.
Authors: B F Leeb; H A Bird; G Nesher; I Andel; W Hueber; D Logar; C M Montecucco; J Rovensky; J Sautner; M Sonnenblick Journal: Ann Rheum Dis Date: 2003-12 Impact factor: 19.103
Authors: Christian Dejaco; Christina Duftner; Marco A Cimmino; Bhaskar Dasgupta; Carlo Salvarani; Cynthia S Crowson; Hilal Maradit-Kremers; Andrew Hutchings; Eric L Matteson; Michael Schirmer Journal: Ann Rheum Dis Date: 2010-11-19 Impact factor: 19.103
Authors: Hao Chen; Donghang Zheng; Sriram Ambadapadi; Jennifer Davids; Sally Ryden; Hazem Samy; Mee Bartee; Eric Sobel; Erbin Dai; Liying Liu; Colin Macaulay; Anthony Yachnis; Cornelia Weyand; Robert Thoburn; Alexandra Lucas Journal: PLoS One Date: 2015-02-06 Impact factor: 3.240